New hope for esophageal cancer: combining immunotherapy with standard treatment
NCT ID NCT04821778
First seen Jan 25, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study looks at whether adding immunotherapy or targeted drugs to standard chemoradiotherapy can help people with esophageal or esophagogastric junction cancer live longer. It involves 2,000 adults with stage I to IVa cancer who are not able to have surgery. The goal is to find the best treatment combination to control the disease and reduce side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department 4th of Radiation Oncology, Anyang Cancer Hospital
RECRUITINGAnyang, Henan, 455001, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
RECRUITINGBeijing, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210009, China
Contact
-
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Email: •••••@•••••
Contact
-
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
RECRUITINGChangsha, Hunan, 410031, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.